Benitec Biopharma Limited announced the appointment of Dr. Claudia Kloth as its Vice President of Manufacturing. Dr. Kloth has more than 14 years of experience in process development and cGMP manufacturing, most recently with gene therapy vectors, including adeno-associated viruses (AAV), which are being used by Benitec in the company's hepatitis C (HCV), hepatitis B (HBV) and age-related macular degeneration (AMD) programs. Dr. Kloth previously led Lonza's process development group in the successful development, optimization, and transfer of robust, viral-based (adenovirus, AAV, lentivirus) and cell therapy products to cGMP manufacturing, through newly established scalable processes. Dr. Kloth is based in the United States and will commence her role with Benitec on 5 January 2015.